1. Home
  2. Knowledge Base
  3. References
  4. Noradrenergic denervation by DBH saporin reduces behavioral responsivity to L-DOPA in the hemi-parkinsonian rat.

Noradrenergic denervation by DBH saporin reduces behavioral responsivity to L-DOPA in the hemi-parkinsonian rat.

Ostock CY, Lindenbach D, Jaunarajs KL, Dupre KB, Goldenberg A, Bhide NS, Bishop C (2012) Noradrenergic denervation by DBH saporin reduces behavioral responsivity to L-DOPA in the hemi-parkinsonian rat. Neuroscience 2012 Abstracts 758.06. Society for Neuroscience, New Orleans, LA.

Summary: Dopamine (DA) replacement therapy with L-DOPA remains the most effective treatment for Parkinson’s disease (PD), but prolonged use frequently leads to deleterious side effects including involuntary choreic and dystonic movements known as L-DOPA induced dyskinesias (LID). It has been well established that DA loss in PD is accompanied by concomitant noradrenergic (NE) denervation of the locus coeruleus (LC); however, the contribution of NE loss to LID remains controversial and is often overlooked in traditional animal models of PD. Previous work from our lab demonstrated that rats with NE depletion induced by the selective NE neurotoxin DA beta hydroxylase saporin (DBH saporin) display reduced behavioral sensitivity to L-DOPA. The current investigation sought to further characterize the utility of DBH saporin lesions in a rodent model of PD by employing immunohistological techniques to correlate NE cell loss with behavioral outcome. Male Spraque-Dawley rats received unilateral 6-OHDA lesions of the medial forebrain bundle with intraventricular injections of either vehicle or DBH saporin. A number of well characterized behavioral tests were employed to determine lesion effects and L-DOPA responsiveness including: the abnormal involuntary movements scale for rodent dyskinesia, the forepaw adjusting steps (FAS) test as a metric of L-DOPA’s anti-parkinsonian efficacy, and locomotor chambers to observe motor performance. Sensitivity of primed animals to different doses of L-DOPA (0-12 mg/kg) and DA agonists SKF81297 (0., 0.08, 0.8 mg/kg) and Quinpirole (0, 0.05, 0.5 mg/kg) was assessed. Reduced behavioral responsiveness was associated with reductions in tyrosine hydroxylase positive cells within the LC of DBH saporin lesioned animals. Results indicate that NE denervation reduced anti-parkinsonian efficacy of L-DOPA on the FAS test. In primed rats, LC NE loss attenuated dyskinetic responses to L-DOPA and the DA agonist SKF81297. Taken together, these results indicate that DBH saporin lesions not only mimick the NE loss seen in idiopathic PD, but also reveal an underexplored contribution of the NE system to the manifestation of PD symptoms and LID.

Related Products: Anti-DBH-SAP (Cat. #IT-03)

Shopping Cart
Scroll to Top